TY - JOUR
T1 - Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics
T2 - A Nationwide Real-World Study in Japan
AU - Onitsuka, Toshiaki
AU - Okada, Tsuyoshi
AU - Hasegawa, Naomi
AU - Tsuboi, Takashi
AU - Iga, Jun Ichi
AU - Yasui-Furukori, Norio
AU - Yamada, Naoki
AU - Hori, Hikaru
AU - Muraoka, Hiroyuki
AU - Ohi, Kazutaka
AU - Ogasawara, Kazuyoshi
AU - Ochi, Shinichiro
AU - Takeshima, Masahiro
AU - Ichihashi, Kayo
AU - Fukumoto, Kentaro
AU - Iida, Hitoshi
AU - Yamada, Hisashi
AU - Furihata, Ryuji
AU - Makinodan, Manabu
AU - Takaesu, Yoshikazu
AU - Numata, Shusuke
AU - Komatsu, Hiroshi
AU - Hishimoto, Akitoyo
AU - Kido, Mikio
AU - Atake, Kiyokazu
AU - Yamagata, Hirotaka
AU - Kikuchi, Saya
AU - Hashimoto, Naoki
AU - Usami, Masahide
AU - Katsumoto, Eiichi
AU - Asami, Takeshi
AU - Kubota, Chika
AU - Matsumoto, Junya
AU - Miura, Kenichiro
AU - Hirano, Yoji
AU - Watanabe, Koichiro
AU - Inada, Ken
AU - Hashimoto, Ryota
N1 - Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2023/7/1
Y1 - 2023/7/1
N2 - Background Although several guidelines recommend monotherapy with antipsychotics for the treatment of schizophrenia, patients who receive long-acting injectable antipsychotics (LAIs) are frequently treated with oral antipsychotics (OAPs). In the present study, we investigated the detailed use of psychotropic medications among patients throughout Japan with schizophrenia who received LAIs or OAPs. Methods The present study used data from the project for the Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment from 94 facilities in Japan. The LAI group included patients who received any LAI, and the non-LAI group included patients who took only OAP medications at discharge. The participants of this study were 2518 schizophrenia patients (263 in the LAI group and 2255 in the non-LAI group) who received inpatient treatment and had prescription information at discharge between 2016 and 2020. Results This study revealed significantly higher rates of polypharmacy antipsychotics, number of antipsychotics, and chlorpromazine equivalents in the LAI group than in the non-LAI group. In contrast, the LAI group showed lower rate of concomitant use of hypnotic and/or antianxiety medication than the non-LAI group. Conclusions Presenting these real-world clinical results, we want to encourage clinicians to keep monotherapy in mind for the treatment of schizophrenia, especially by reducing concomitant use of antipsychotics in the LAI group and reducing hypnotic and/or antianxiety medication in the non-LAI group.
AB - Background Although several guidelines recommend monotherapy with antipsychotics for the treatment of schizophrenia, patients who receive long-acting injectable antipsychotics (LAIs) are frequently treated with oral antipsychotics (OAPs). In the present study, we investigated the detailed use of psychotropic medications among patients throughout Japan with schizophrenia who received LAIs or OAPs. Methods The present study used data from the project for the Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment from 94 facilities in Japan. The LAI group included patients who received any LAI, and the non-LAI group included patients who took only OAP medications at discharge. The participants of this study were 2518 schizophrenia patients (263 in the LAI group and 2255 in the non-LAI group) who received inpatient treatment and had prescription information at discharge between 2016 and 2020. Results This study revealed significantly higher rates of polypharmacy antipsychotics, number of antipsychotics, and chlorpromazine equivalents in the LAI group than in the non-LAI group. In contrast, the LAI group showed lower rate of concomitant use of hypnotic and/or antianxiety medication than the non-LAI group. Conclusions Presenting these real-world clinical results, we want to encourage clinicians to keep monotherapy in mind for the treatment of schizophrenia, especially by reducing concomitant use of antipsychotics in the LAI group and reducing hypnotic and/or antianxiety medication in the non-LAI group.
KW - combination psychotropic use
KW - long-acting injectable antipsychotics
KW - oral antipsychotics
KW - schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85164069426&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85164069426&partnerID=8YFLogxK
U2 - 10.1097/JCP.0000000000001704
DO - 10.1097/JCP.0000000000001704
M3 - Article
C2 - 37216369
AN - SCOPUS:85164069426
SN - 0271-0749
VL - 43
SP - 365
EP - 368
JO - Journal of Clinical Psychopharmacology
JF - Journal of Clinical Psychopharmacology
IS - 4
ER -
